- Akzo Nobel NV
- Akzo Pharma International BV
- Lexicon Pharmaceuticals Inc.
- Diosynth BV
- Eli Lilly & Co.
- Pfizer Inc.
- GlaxoSmithKline PLC
- UCB Group
- Merck Serono SA
- Laboratorios del Dr. Esteve SA
- Cypress Bioscience Inc.
- Ligand Pharmaceuticals Inc.
- Merck KGaA
- Laboratoire Theramex
- Solvay SA
- Solvay Pharmaceuticals SA
- J. Uriach & Cia SA
- Genentech Inc.
- Bristol-Myers Squibb Co.
- Takeda Pharmaceutical Co. Ltd.
- Entelos Inc.
- Altana AG
- Lexicon Genetics and Organon in drug development agreement
- UCB and Celltech to develop and market CDP870 for arthritis
- Pfizer, Akzo Nobel's Organon develop antipsychotic drug
- Organon to co-promote Ligand's Avinza; terminated
- Organon gets rights to Merck KGAA's oral contraceptive
- Uriach, Organon develop inflammatory disorder therapies
- Genentech, Lexicon enter 3-year drug discovery deal
- BMS and Lexicon Genetics in target validation deal
- Takeda uses Lexicon's targets for hypertension discovery
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.